Erratum: Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. Hospitals during 2016 to 2018 (Antimicrobial Agents and Chemotherapy (2020) 64:2 (e01951-19) DOI: 10.1128/AAC.01951-19);Meropenem-vaborbactam activity against carbapenem-resistant enterobacterales isolates collected in U.S. Hospitals during 2016 to 2018

Antimicrobial Agents and Chemotherapy

Volumn 64, Issue 2, 2020, Pages

  Castanheira, Mariana ^a   Doyle, Timothy B ^a   Kantro, Valerie ^a   Mendes, Rodrigo E ^a   Shortridge, Dee ^a  

^a JMI LABORATORIES   (United States)

Author keywords

CRE; Enterobacterales; Outer membrane protein

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBAPENEMASE; COLISTIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; MEROPENEM PLUS VABORBACTAM; MINOCYCLINE; OUTER MEMBRANE PROTEIN; PENICILLINASE; TIGECYCLINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; BORONIC ACID DERIVATIVE; CARBAPENEM DERIVATIVE; OUTER MEMBRANE PROTEIN C; OUTER MEMBRANE PROTEIN F; PORIN; VABORBACTAM;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CARBAPENEM RESISTANCE; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CITROBACTER FREUNDII; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; GEOGRAPHIC DISTRIBUTION; HOSPITAL; HUMAN; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY RATE; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEUS MIRABILIS; RAOULTELLA; SERRATIA MARCESCENS; UNITED STATES; DRUG EFFECT; ENZYMOLOGY; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; BORONIC ACIDS; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CARBAPENEMS; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MEROPENEM; MICROBIAL SENSITIVITY TESTS; PORINS; UNITED STATES;

EID: 85078461415     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00305-20     Document Type: Erratum

References (32)

1. Logan LK, Weinstein RA. 2017. The epidemiology of carbapenem-resistant Enterobacteriaceae: The impact and evolution of a global menace. J Infect Dis 215:S28-S36. https://doi.org/10.1093/infdis/jiw282.
2. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
3. Martin A, Fahrbach K, Zhao Q, Lodise T. 2018. Association between carbapenem resistance and mortality among adult, hospitalized patients with serious infections due to Enterobacteriaceae: Results of a systematic literature review and meta-analysis. Open Forum Infect Dis 5:ofy150. https://doi.org/10.1093/ofid/ofy150.
4. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A. 2014. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322-2328. https://doi.org/10.1128/AAC.02166-13.
5. Lodise TP, Berger A, Altincatal A, Wang R, Bhagnani T, Gillard P, Bonine NG. 2019. Antimicrobial resistance or delayed appropriate therapy- does one influence outcomes more than the other among patients with serious infections due to carbapenem-resistant versus carbapenemsusceptible Enterobacteriaceae? Open Forum Infect Dis 6:ofz194. https://doi.org/10.1093/ofid/ofz194.
6. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis 55: 943-950. https://doi.org/10.1093/cid/cis588.
7. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagace-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, III, Karlowsky JA. 2013. Ceftazidime-avibactam: A novel cephalosporin/-lactamase inhibitor combination. Drugs 73:159 -177. https://doi.org/10.1007/s40265 -013-0013-7.
8. Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Doi Y, Kreiswirth BN, Clancy CJ. 2017. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 61:e00883-17. https://doi.org/10.1128/AAC.00883-17.
9. Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, Clancy CJ. 2017. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 61:e02097-16. https://doi.org/10.1128/AAC.02097-16.
10. Nelson K, Hemarajata P, Sun D, Rubio-Aparicio D, Tsivkovski R, Yang S, Sebra R, Kasarskis A, Nguyen H, Hanson BM, Leopold S, Weinstock G, Lomovskaya O, Humphries RM. 2017. Resistance to ceftazidime-avibactam is due to transposition of KPC in a porin-deficient strain of Klebsiella pneumoniae with increased efflux activity. Antimicrob Agents Chemother 61:e00989-17. https://doi.org/10.1128/AAC.00989-17.
11. Castanheira M, Arends SJR, Davis AP, Woosley LN, Bhalodi AA, MacVane SH. 2018. Analyses of a ceftazidime-avibactam-resistant Citrobacter freundii isolate carrying blaKPC-2 reveals a heterogenous population and reversible genotype. mSphere 3:e00408-18. https://doi.org/10.1128/mSphere.00408-18.
12. Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagace-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, III, Karlowsky JA. 2018. Imipenem-relebactam and meropenem-vaborbactam: Two novel carbapenem-beta-lactamase inhibitor combinations. Drugs 78:65-98. https://doi.org/10.1007/s40265 -017-0851-9.
13. Griffith DC, Sabet M, Tarazi Z, Lomovskaya O, Dudley MN. 2019. Pharmacokinetics/pharmacodynamics of vaborbactam, a novel beta-lactamase inhibitor, in combination with meropenem. Antimicrob Agents Chemother 63: E01659-18. https://doi.org/10.1128/AAC.01659-18.
14. Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN. 2017. Vaborbactam: Spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother 61:e01443-17. https://doi.org/10.1128/AAC.01443-17.
15. Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, Vazquez J, Zaitsev V, Bidair M, Chorvat E, Dragoescu PO, Fedosiuk E, Horcajada JP, Murta C, Sarychev Y, Stoev V, Morgan E, Fusaro K, Griffith D, Lomovskaya O, Alexander EL, Loutit J, Dudley MN, Giamarellos-Bourboulis EJ. 2018. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: The TANGO I randomized clinical trial. JAMA 319:788-799. https://doi.org/10.1001/jama.2018.0438.
16. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS. 2018. Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: The TANGO II randomized clinical trial. Infect Dis Ther 7:439-455. https://doi.org/10.1007/s40121-018-0214-1.
17. Castanheira M, Huband MD, Mendes RE, Flamm RK. 2017. Meropenemvaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPCproducing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother 61:e00567-17. https://doi.org/10.1128/AAC.00567-17.
18. Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M. 2018. In vitro activity of meropenem/vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance program. Int J Antimicrob Agents 52:144 -150. https://doi.org/10.1016/j.ijantimicag.2018.02.021.
19. Wilson WR, Kline EG, Jones CE, Morder KT, Mettus RT, Doi Y, Nguyen MH, Clancy CJ, Shields RK. 2019. Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenemresistant Enterobacteriaceae. Antimicrob Agents Chemother 63:e02048-18. https://doi.org/10.1128/AAC.02048-18.
20. Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. 2018. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother 62: E01904-17. https://doi.org/10.1128/AAC.01904-17.
21. Satlin MJ, Chen L, Patel G, Gomez-Simmonds A, Weston G, Kim AC, Seo SK, Rosenthal ME, Sperber SJ, Jenkins SG, Hamula CL, Uhlemann AC, Levi MH, Fries BC, Tang YW, Juretschko S, Rojtman AD, Hong T, Mathema B, Jacobs MR, Walsh TJ, Bonomo RA, Kreiswirth BN. 2017. Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother 61:e02349-16. https://doi.org/10.1128/AAC.02349-16.
22. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56: 2108-2113. https://doi.org/10.1128/AAC.06268-11.
23. Bassetti M, Giacobbe DR, Patel N, Tillotson G, Massey J. 2019. Efficacy and safety of meropenem-vaborbactam versus best available therapy for the treatment of carbapenem-resistant Enterobacteriaceae infections in patients without prior antimicrobial failure: A post hoc analysis. Adv Ther 36: 1771-1777. https://doi.org/10.1007/s12325-019-00981-y.
24. Athans V, Neuner EA, Hassouna H, Richter SS, Keller G, Castanheira M, Brizendine KD, Mathers AJ. 2018. Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient. Antimicrob Agents Chemother 63:e01551. https://doi.org/10.1128/AAC.01551-18.
25. Clinical and Laboratory Standards Institute. 2018. M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 11th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
26. Clinical and Laboratory Standards Institute. 2019. M100Ed29. Performance standards for antimicrobial susceptibility testing: 29th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
27. EUCAST. 2019. Breakpoint tables for interpretation of MICs and zone diameters, version 9.0, January 2019. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpoint _Tables.pdf. Accessed January 2019.
28. FDA. 2019. Antibacterial susceptibility test interpretive criteria. https://www.fda.gov/drugs/development-resources/antibacterial-susceptibility -test-interpretive-criteria. Accessed 5 May 2019.
29. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G, Alekseyev MA, Pevzner PA. 2012. SPAdes: A new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455-477. https://doi.org/10.1089/cmb.2012.0021.
30. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. 2009. BLAST: Architecture and applications. BMC Bioinformatics 10:421. https://doi.org/10.1186/1471-2105-10-421.
31. Castanheira M, Mendes RE, Sader HS. 2017. Low frequency of ceftazidimeavibactam resistance among Enterobacteriaceae Isolates Carrying blaKPC collected in U.S.hospitals from 2012 to 2015. Antimicrob Agents Chemother 61:e02369-16. https://doi.org/10.1128/AAC.02369-16.
32. Castanheira M, Costello SE, Woosley LN, Deshpande LM, Davies TA, Jones RN. 2014. Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel -lactamases, GES-22 and VIM-35. Antimicrob Agents Chemother 58:7358 -7366. https://doi.org/10.1128/AAC.03930-14.